Pemetrexed is widely employed for the clinical management of mesothelioma and non-small cell lung carcinoma, largely based on its ability to curtail folate metabolism in highly proliferating cells. Recent preclinical findings suggest that the therapeutic efficacy of pemetrexed may involve an unsuspected immunologic component.See related article by Schaer et al., p. 7175.
©2019 American Association for Cancer Research.